9999999997-11-011004.txt : 20110603
9999999997-11-011004.hdr.sgml : 20110603
20110602171805
ACCESSION NUMBER: 9999999997-11-011004
CONFORMED SUBMISSION TYPE: CT ORDER
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20110603
DATE AS OF CHANGE: 20110602
20110603
20110602
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000890465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 870439579
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: CT ORDER
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23272
FILM NUMBER: 11889379
BUSINESS ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: (908) 450-5300
MAIL ADDRESS:
STREET 1: 550 HILLS DRIVE
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
CT ORDER
1
filename1.pdf
begin 644 filename1.pdf
M)5!$1BTQ+C4-)>+CS],-"C$P(#`@;V)J#3P\+TQI;F5A7!E+UA2968O5ULQ(#(@,5T^/G-T#0IE;F1S
M=')E86T-96YD;V)J#7-T87)T>')E9@T*,`T*)25%3T8-"B`@("`@("`@#0HR
M,B`P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22`X-"],(#8X+TQE;F=T
M:"`V,2]3(#,X/CYS=')E86T-"FC>8F!@8&9@8.)G``(.7!E+T-A=&%L;V<^/@UE;F1O8FH-,3(@
M,"!O8FH-/#PO0V]N=&5N=',@,30@,"!2+T-R;W!";WA;,"`P(#8Q,B`W.3)=
M+TUE9&EA0F]X6S`@,"`V,3(@-SDR72]087)E;G0@."`P(%(O4F5S;W5R8V5S
M(#$V(#`@4B]2;W1A=&4@,"]4>7!E+U!A9V4^/@UE;F1O8FH-,3,@,"!O8FH-
M/#PO1FEL=&5R+T9L871E1&5C;V1E+T9II%+;;MLP#/T5/FX/F2Z^2`:*`$G;
M=`.6+JB-=4"0!RW1$@.^!+:*I7\_4;(3UT"QK84@D^8AS4/SL!@H,`$B`2:!
M!=8D$`@.G(*0%#@#1JF`JRMR>S)WJ5%&6_\N95A%X6$Z)8NZ,C:691R+;-74VU2;-5G=+$BF3V8SG=KT;ROXI8I66V<)C*2S[C5=`OU$.C_K2
MD]1'C[O:6;O5E0&9,'*MCI]UOC\8Y$G)C?;0A+.8+`JU;R$('/Z0Y:5NX5[_AH>Z5-5'A]VK4A.'6,#%5^ED7A>[
M9>;PU#3:;`_DOFY*5;C0HZM&-VIF<_O3.'=LTC"G@BZNWP(!8$`?@[%8-MW?L2]S[%L0L,XDV/N>#@
M']XB!T)G2(<^Q/N>`UO\CU-Y>>T1L.*_>VP(-J,L@'AB9FR/1M%ITJ:.PR)Y
MR@Q>>\_D:3&/IY;MTXA,8&79`0U);%%&1K&>G9I)L/Z,[WOV@(9A<(GI#`RF
M'$C,U73\M)S'8'0F.(>%Q.9DNX)P!BSS)O4M\`XAY^"A2M.4ZJ-!W00?6`;P0+_
M3(`SD7-8E!30LNUZ;NB"#>/9+^X@]%WM+77/Q$G^NO53&[$:?%T-DE&C/O\D
M<^<=P^DQ43)BL&PW#)QCY#+P(=DG)FH5<(%AUNUZ;PV):!J>05)`\OK1A1;S5/\JRJO(^^NX3TMBPW2ZA&1
M\:(1DFQ&S<8<:=##95B>%BAJ'9<9C^V(FU:&IH2DA@5E9FC3GV[[#!
M9&:=J#7R!>7L2+DN4O3L(7GKRI2J+"$OUYK15#G^\;1_F;`O28UF$:SBAXK7
M2(V*&L/U20WK-SAI>8@IZ1*JR,HM#Z>ZU#:[I,&+J"699;=?4=@E33K@*P?(
M]S;)Q4;P&I(:9-Y,RG)\V.]YEOQUJT-?2MIL4[O;^*/`?I[IJCSG*N
M-(>N2SCE';Y$PY-W5U)_)CI$M*R3V0C)5T2X):T2./!*E%D-]8&G4E/9Y\XU
MA?O3?FIJ0[41;'I^%)K:@*Y4P5)%PAR*+T(6^:J0J[+=[LS*A*='(AE_]\B9
M'V$SXW*`GZSX):$H,#%P(79%[1
M-XU[_PHP`!ME\BD-"F5N9'-T,E,P4#!7,+10L+'1]RO-+8X&<0T4@F+M[(`BP?HN
M=G8``08`C84(-PT*96YDFMC
M.60B/SX*/'@Z>&UP;65T82!X;6QN#IX
M;7!T:STB061O8F4@6$U0($-O&%P+S$N,"\B/@H@("`@("`@("`\>&UP.D-R96%T;W)4;V]L/E!38W)I
M<'0U+F1L;"!697)S:6]N(#4N,BXR/"]X;7`Z0W)E871O&UL;G,Z9&,](FAT='`Z+R]P=7)L
M+F]R9R]D8R]E;&5M96YT"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M(#(V-S0R
M+F]R9&5R+F1O8SPO&UP34TZ26YS=&%N8V5)1#YU=6ED.F)D.#)D9#AE+61E8V0M-#=F
M8BTX93,P+64X9C@U8V5C838X.#PO>&UP34TZ26YS=&%N8V5)1#X*("`@("`@
M/"]R9&8Z1&5S8W)I<'1I;VX^"B`@(#POJ'5!:DZ@F1Z#`)-6"3$Z!GVIC`(
M=]6'R=%GN6N=78-$K]JPN0L]!7IB!RE@M2O0;.S9.!KUZ?058`#VHD"_#0IE
M;F1S=')E86T-96YD;V)J#34@,"!O8FH-/#PO1&5C;V1E4&%R;7,\/"]#;VQU
M;6YS(#0O4')E9&EC=&]R(#$R/CXO1FEL=&5R+T9L871E1&5C;V1E+TE$6SQ$
M.$8Q134V-C8V,4)&04%%-30Y0D8Y03=#,S(Q.#$W.#X\-S,V,SDW0CQ`B:>;@"P&!D8@P?0?2#`R``08
M`'I*!1L-"F5N9'-T